Navigation Links
Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Date:12/9/2012

roduce and store extra blood cells, which can cause these organs to become enlarged.

Most patients with MF have greatly enlarged spleens (splenomegaly) that can result in a range of vague symptoms with dramatic impact on quality of life.  These include fatigue, abdominal pain, night sweats, feeling full without eating, cough or shortness of breath and decreased physical activity. Other signs and symptoms of MF include anemia, thrombocytopenia, weight loss and severe itching.

The exact prevalence of MF is not known.  The latest research estimates that the prevalence of MF ranges from 4.2 to 5.6 per 100,000 people in the U.S., or approximately 15,000 patients.  Prevalence estimates in Europe are less clear.  People over age sixty are most likely to develop this disease, with men and women equally at risk.

About JAK2 and SAR302503
JAK2 is a key enzyme for blood cell development. Mutations in JAK2 can lead to dysregulated JAK2 signaling and are thought to be a cause of MF.  Patients with wild type JAK2 have also been shown to have persistent, dysregulated activation of the JAK2 signaling pathway.

SAR302503 is a novel, investigational, selective inhibitor of the JAK/STAT signaling pathway that preferentially inhibits JAK2.  Sanofi Oncology is developing the compound for the treatment of the three main types of myeloproliferative neoplasms: primary myelofibrosis, polycythemia vera and essential thrombocythemia. Sanofi is also studying the effect of the compound on reducing/reversing scarring in the bone marrow. 

About Sanofi Oncology
Based in Cambridge, Massachusetts, USA and Vitry, France, Sanofi Oncology is dedicated to translating science into effective therapeutics that address unmet medical needs for cancer and organ transplant patients. Starting with a deep understanding of the disease and the patient, Sanofi Oncology employs innovative approaches to drug discovery and clinic
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... BOSTON , December 15, 2014 ... discovery and development company, is pleased to announce the ... United States relating to its GPCR-focused drug ... US significantly strengthens the global patent estate covering Heptares, ... The suite of patents recently granted by the ...
(Date:12/13/2014)... , Dec. 12, 2014  Radiologists can transmit ... images, to their referring physicians, electronic health records ... carefully selected technology.  That was ... Systems Corporation (ADS) at the recent Radiology Society ... transmitting of radiology reports in this manner also ...
(Date:12/13/2014)... and INDIANAPOLIS , Dec. 12, ... and Chip Ganassi Racing Teams (CGRT), today announced a multi-year ... the primary sponsor of the No. 83 Novo Nordisk Chip ... the Verizon IndyCar Series. Kimball, 29, from ... only licensed driver with diabetes in the history of INDYCAR ...
Breaking Medicine Technology:Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2Advanced Data Systems Presents on Interface-Free EHR Communications at RSNA's 2014 Conference: Streamlining Communication of Reports and Images to Referring Physicians 2Advanced Data Systems Presents on Interface-Free EHR Communications at RSNA's 2014 Conference: Streamlining Communication of Reports and Images to Referring Physicians 3Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 3Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 4Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 5Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 6Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 7
... August 27 , - Oralair(R) Grasses 300IR Highly ... Allergen Challenge Chamber, Stallergenes S.A. announces the highly ... Challenge Chamber (ACC)., The study on Oralair(R) Grasses ... different treatment durations: 1 week, 1 month,2 and 4 ...
... INDIANAPOLIS, Aug. 26 Semafore Pharmaceuticals Inc.,announced data ... in Cancer in Washington, D.C., showing additional antiangiogenic,activity ... both VEGF and Bv8 signaling., PI3K is ... /mTOR pathway that,has been shown to play a ...
Cached Medicine Technology:Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 2Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 3SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... ... medical device industry expands its precision micro-machining facility, increases work force to three shifts ... ... Medical,s San Diego facility has completed a multi-million dollar expansion in order to integrate ...
... NEW YORK, Oct. 20 Philips is delivering on their ... the launch of Philips DirectLife, a new customized, interactive fitness ... eager to adopt a more active lifestyle. The DirectLife program ... the more than 60 percent of the global population who ...
... announced a donation of $211,306 from Eagle Golf, the Dallas-based ... Club at Castle Hills in Lewisville, Texas. From Sept. 1-Oct. ... a Swing at Cancer" to raise awareness and funds for the ... Eagle Golf and its patrons for supporting our work on behalf ...
... children are already anticipating Halloween "trick or treating," some parents ... door-to-door to receive free candy. , Parents of ... when their child is the recipient of food outside the ... allergy can stay safe without having to miss out on ...
... lie when it comes to showing signs of aging. Yet ... Studies have demonstrated that volume loss of soft tissue and ... loss of volume in the face over time can cause deep ... With the recent FDA approval of Scrulptra® Aesthetic, physicians now have ...
... 1. For Patients with Erectile Dysfunction, Treatment with ... and Erectile Function , ACP issues clinical practice ... inhibitor drugs used to treat patients with ED, ... the treatment of erectile dysfunction (ED). ACP strongly ...
Cached Medicine News:Health News:Johnson Matthey Expands San Diego Facility 2Health News:Philips Launches DirectLife, a New Personal Fitness Program to Help People Lead Healthier Lives 2Health News:Philips Launches DirectLife, a New Personal Fitness Program to Help People Lead Healthier Lives 3Health News:Philips Launches DirectLife, a New Personal Fitness Program to Help People Lead Healthier Lives 4Health News:LIVESTRONG(R) Receives $211,306 Donation from Eagle Golf 2Health News:Halloween Doesn't Have to Be Scary for Kids With Food Allergies 2Health News:Pumping Up the Volume in the Face to Reduce Signs of Aging 2Health News:Pumping Up the Volume in the Face to Reduce Signs of Aging 3Health News:Embargoed news from Annals of Internal Medicine 2Health News:Embargoed news from Annals of Internal Medicine 3
... the art in inverted microscopy from Zeiss. ... range of ICS objectives, with innovative condensers ... an unusual scope of sophisticated documentation and ... designed. And Axiovert 200 M, fully motorized, ...
... TS100 is an innovative and efficient ... tool complements any research facility. Improved ... Nikon offers the TS100 binocular and ... model comes with a photo port ...
... direct digital output. Three-chip color camera for ... array of high-quality color video cameras give ... you need for an efficient viewing experience. ... image of your specimen that can be ...
... Tech GT-Capture digital camera photomicrographic system can ... such as Olympus, Leica, Nikon, and Zeiss, ... transferring images over the Internet easy and ... a performance-proven Nikkor lens. The system records ...
Medicine Products: